明德生物
(002932)
| 流通市值：30.26亿 | | | 总市值：45.09亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 139,289,387.41 | 69,960,271.6 | 350,061,800.61 | 225,617,843.38 |
| 营业收入 | 139,289,387.41 | 69,960,271.6 | 350,061,800.61 | 225,617,843.38 |
| 二、营业总成本 | 206,076,837.66 | 114,191,703.22 | 432,523,176.2 | 319,893,245.81 |
| 营业成本 | 82,428,533.9 | 58,506,453.08 | 161,410,575.99 | 108,759,792.33 |
| 税金及附加 | 1,962,320.88 | 925,080.89 | 1,507,707.19 | 992,146.35 |
| 销售费用 | 48,440,057.66 | 18,619,395.34 | 85,322,167.97 | 78,658,773.4 |
| 管理费用 | 27,703,638.13 | 13,290,488.75 | 84,287,503.42 | 51,979,156.29 |
| 研发费用 | 46,818,891.76 | 24,550,271.02 | 109,551,499.12 | 86,244,236.06 |
| 财务费用 | -1,276,604.67 | -1,699,985.86 | -9,556,277.49 | -6,740,858.62 |
| 其中:利息费用 | 59,150 | 29,250 | 1,284,903.85 | 470,919.47 |
| 其中:利息收入 | 2,977,064.61 | 2,194,992.86 | 10,400,731.61 | 8,205,047.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,149,546.14 | - | 1,736,551.64 | 637,059.61 |
| 加:投资收益 | 49,937,682.75 | 27,005,803.92 | 133,703,042.86 | 78,456,046.18 |
| 资产处置收益 | 74,004.12 | - | 1,792,048.58 | 82,278.11 |
| 资产减值损失(新) | 0 | - | -86,919,196.43 | 0 |
| 信用减值损失(新) | 2,437,975.49 | 14,258,490.11 | -4,007,552.47 | 26,852,344.74 |
| 其他收益 | 24,965,625.83 | 539,924.11 | 77,343,383.3 | 70,528,745.56 |
| 四、营业利润 | 9,478,291.8 | -2,427,213.48 | 41,186,901.89 | 82,281,071.77 |
| 加:营业外收入 | 125,332.72 | 26,975.57 | 3,820,836.87 | 338,528.65 |
| 减:营业外支出 | 2,802,666.94 | 1,569,400.87 | 12,591,770.34 | 4,544,957.62 |
| 五、利润总额 | 6,800,957.58 | -3,969,638.78 | 32,415,968.42 | 78,074,642.8 |
| 减:所得税费用 | 175,121.18 | -564,464.79 | 5,851,251.93 | 15,710,870.64 |
| 六、净利润 | 6,625,836.4 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,625,836.4 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,497,336.94 | -3,662,988.06 | 74,519,615.72 | 80,938,367.97 |
| 少数股东损益 | -5,871,500.54 | 257,814.07 | -47,954,899.23 | -18,574,595.81 |
| 扣除非经常损益后的净利润 | -35,621,769.6 | -14,803,714.02 | -140,346,823.73 | -39,076,564.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | -0.02 | 0.33 | 0.35 |
| (二)稀释每股收益 | 0.06 | -0.02 | 0.33 | 0.35 |
| 九、综合收益总额 | 6,625,836.4 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 |
| 归属于母公司股东的综合收益总额 | 12,497,336.94 | -3,662,988.06 | 74,519,615.72 | 80,938,367.97 |
| 归属于少数股东的综合收益总额 | -5,871,500.54 | 257,814.07 | -47,954,899.23 | -18,574,595.81 |
| 公告日期 | 2025-08-28 | 2025-04-30 | 2025-04-25 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |